Device Trial Radar · NCT07087639
Novel Venous Cannula Trial
Last checked: Nov 20, 2026Latest source record: Jul 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Dec 22, 2022
Primary completion
Feb 5, 2025
Study completion Feb 5, 2025
Sponsor
- Lead sponsor
- Eurosets S.r.l.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 28, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, open-label, single-arm, single-center clinical investigation designed to evaluate the safety and performance of a Novel Venous Cannula during on-pump cardiac surgery requiring transfemoral venous cannulation. The investigation aims to assess the pressure drop across the cannula during extracorporeal circulation and the incidence of serious adverse events associated with its use. A total of 42 participants will be enrolled.
Conditions
- Cardiac Surgery
- Heart Surgery
- Cardiopulmonary Bypass
- Minimally Invasive Surgical Procedures
Interventions
Self-expanding Venous CannulaDevice
The intervention consists of a self-expanding venous drainage cannula made of polyurethane and reinforced with a flexible metallic mesh. It is designed for transfemoral insertion during on-pump cardiac surgery, including minimally invasive procedures. Once positioned, the cannula expands to its functional diameter to facilitate efficient blood drainage into the extracorporeal circulation system. The configuration used in this study is 680/730 mm in length, 24 Fr, 3/8" diameter. The device is sterile, single-use, and is inserted once on the day of surgery (Day 0) and removed at the end of the procedure. The cannula is used continuously during cardiopulmonary bypass for a maximum duration of 6 hours and is not reused.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effectiveness: the mean pressure drop (mm Hg) to maintain the desired flow rate (L/min) during the standard surgical procedureTime frame: During the surgical procedure (Day 0)
- Safety: the number of SAE with the Novel Venous Cannula during the standard surgical procedureTime frame: From Day 0 (procedure day) to 7 days post-procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Maria Cecilia Hospital
Cotignola, RA, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.